Peritonitis Clinical Trial
Official title:
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
The major hypothesis to be tested is that the treatment of intraabdominal infections that have been adequately treated operatively or by percutaneous techniques with three to five days of antibiotics will result in outcomes equivalent to the current standard where treatment is carried out until the patient has returned to normal (normal white blood cell count, temperature, and intestinal function), and that patients treated for three to five days will receive fewer days of antibiotics than the control group that has traditionally received seven to 14 days of treatment.
Overall, this is a prospective, randomized, single-blinded (analysis), fifteen-center study using intent to treat analysis. Patients will be identified and after informed consent is obtained, will be randomized to receive antibiotics for 3 to 5 days (4 ± 1 days) after the initial surgical or percutaneous intervention or antibiotics until two calendar days after the patient's white blood cell count, systemic temperature, and gastrointestinal function have normalized (maximum of 10 days). The primary endpoint is the composite rate of in-hospital death and/or recurrence of intraabdominal infection and/or occurrence of surgical site (wound) infection. Secondary endpoints include the occurrence of any infection at any site and infection with antibiotic-resistant pathogens. Patient data through the thirty days following the initial intervention or until hospital discharge (whichever is longer) will be tracked ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04070196 -
Point-of-care Test for Diagnosis of Peritonitis in Peritoneal Dialysis Patients
|
N/A | |
Recruiting |
NCT00131196 -
Functional Genomic Influences on Disease Progression and Outcome in Sepsis
|
N/A | |
Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
Completed |
NCT04182217 -
Descriptive and Correlational Study of Peritonitis in Haiti.
|
||
Recruiting |
NCT03310606 -
Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis
|
N/A | |
Completed |
NCT01222663 -
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
|
Phase 3 | |
Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
Recruiting |
NCT03790176 -
ZAVI APD ELF Protocol v2.2
|
Phase 1 | |
Completed |
NCT03668197 -
Children Peritonitis Ecology at CHU de Rennes - (IIAPEDIA)
|
||
Recruiting |
NCT01837342 -
Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
|
N/A | |
Completed |
NCT00497744 -
A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis
|
N/A | |
Recruiting |
NCT03334006 -
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis (PEPPER Trial).
|
Phase 2 | |
Terminated |
NCT03403751 -
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
|
Phase 3 | |
Withdrawn |
NCT00463762 -
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
|
Phase 4 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Not yet recruiting |
NCT05308849 -
Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis
|
N/A | |
Completed |
NCT02726932 -
Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery
|
||
Recruiting |
NCT05050253 -
Lavage With Super-Oxidized Solution for Secondary Peritonitis
|
N/A | |
Completed |
NCT02926846 -
IV Antibiotics With Lavage for Severe PD Peritonitis
|
Phase 4 | |
Completed |
NCT01793688 -
Drug Use Investigation Of Sulbactam/Ampicillin (UNASYN) 12g (Regulatory Post Marketing Commitment Plan)
|
N/A |